251 related articles for article (PubMed ID: 30343892)
1. Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors.
Chen CY; Wu VC; Lin CJ; Lin CS; Pan CF; Chen HH; Lin YF; Huang TM; Chen L; Wu CJ;
Mayo Clin Proc; 2018 Dec; 93(12):1760-1774. PubMed ID: 30343892
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
Kornelius E; Huang CN; Lo SC; Wang YH; Yang YS
Endocr Pract; 2020 Dec; 26(12):1486-1496. PubMed ID: 33471741
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes.
Chao CT; Wang J; Wu HY; Chien KL; Hung KY
Oncotarget; 2017 Aug; 8(32):53028-53040. PubMed ID: 28881791
[TBL] [Abstract][Full Text] [Related]
4. Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan.
Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Hsiao KY; Wu MJ; Shieh JJ; Huang YC; Chung CJ
JAMA Netw Open; 2023 Feb; 6(2):e230453. PubMed ID: 36811856
[TBL] [Abstract][Full Text] [Related]
5. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
6. Effects of Higher Quality of Care on Initiation of Long-term Dialysis in Patients With CKD and Diabetes.
Wu HY; Fukuma S; Shimizu S; Norton EC; Tu YK; Hung KY; Chen MR; Chien KL; Fukuhara S
Am J Kidney Dis; 2017 Nov; 70(5):666-674. PubMed ID: 28764919
[TBL] [Abstract][Full Text] [Related]
7. Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin-Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease.
Al Tuhaifi T; Zhong J; Yang HC; Fogo AB
Lab Invest; 2024 Feb; 104(2):100305. PubMed ID: 38109999
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
[TBL] [Abstract][Full Text] [Related]
10. Association of Renal and Cardiovascular Safety With DPP-4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Yang CT; Lin WH; Li LJ; Ou HT; Kuo S
Clin Pharmacol Ther; 2021 Aug; 110(2):464-472. PubMed ID: 33866549
[TBL] [Abstract][Full Text] [Related]
11. Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes.
Na Y; Kim SW; Park IB; Choi SJ; Nam S; Jung J; Lee DH
J Clin Endocrinol Metab; 2022 Nov; 107(11):3022-3034. PubMed ID: 36108097
[TBL] [Abstract][Full Text] [Related]
12. Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
Chan SY; Ou SM; Chen YT; Shih CJ
Int J Cardiol; 2016 Sep; 218():170-175. PubMed ID: 27236110
[TBL] [Abstract][Full Text] [Related]
13. Ketoanalogue supplements reduce mortality in patients with pre-dialysis advanced diabetic kidney disease: A nationwide population-based study.
Chen HY; Sun CY; Lee CC; Wu IW; Chen YC; Lin YH; Fang WC; Pan HC
Clin Nutr; 2021 Jun; 40(6):4149-4160. PubMed ID: 33597108
[TBL] [Abstract][Full Text] [Related]
14. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
15. Non-recovery from dialysis-requiring acute kidney injury and short-term mortality and cardiovascular risk: a cohort study.
Lee BJ; Hsu CY; Parikh RV; Leong TK; Tan TC; Walia S; Liu KD; Hsu RK; Go AS
BMC Nephrol; 2018 Jun; 19(1):134. PubMed ID: 29890946
[TBL] [Abstract][Full Text] [Related]
16. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
Chung YR; Ha KH; Lee K; Kim DJ
PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
[TBL] [Abstract][Full Text] [Related]
17. Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study.
Shih CJ; Lee YJ; Lo YH; Kuo SC; Ou SM; Chen YT
Mayo Clin Proc; 2016 Jul; 91(7):867-72. PubMed ID: 27236426
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Seong JM; Yee J; Gwak HS
Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554
[TBL] [Abstract][Full Text] [Related]
19. Clinical Predictors and Long-term Impact of Acute Kidney Injury on Progression of Diabetic Kidney Disease in Chinese Patients With Type 2 Diabetes.
Jiang G; Luk AO; Tam CHT; Ozaki R; Lim CKP; Chow EYK; Lau ES; Kong APS; Fan B; ; Lee KF; Siu SC; Hiu G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; ; Tang NLS; Huang Y; Lan HY; Oram RA; Szeto CC; So WY; Chan JCN; Ma RCW
Diabetes; 2022 Mar; 71(3):520-529. PubMed ID: 35043149
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
White WB; Wilson CA; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Heller SK; Mehta CR; Nissen SE; Zannad F; Kupfer S;
Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
